We earn commissions from brands listed on this site, which influences how listings are presented. Advertising Disclosure

Ozempic vs Wegovy: Same Drug, Different Labels, Different Rules

Ozempic and Wegovy are both semaglutide. The differences are dose ceilings, FDA labels, insurance treatment, and price channels, and those differences decide what you actually pay.

Key Takeaways

Ozempic and Wegovy contain the identical drug: semaglutide. Ozempic is FDA-approved for type 2 diabetes with doses up to 2mg weekly; Wegovy is approved for weight management with doses up to 2.4mg. Insurance follows the label, not the molecule: diabetes coverage applies to Ozempic, weight loss coverage (or exclusions) applies to Wegovy. If you do not have diabetes, Wegovy through NovoCare at $499 per month or compounded semaglutide from $99 are your realistic channels.

Ozempic vs Wegovy at a Glance

FeatureOzempicWegovy
Active ingredientSemaglutideSemaglutide (identical)
FDA labelType 2 diabetes (2017)Chronic weight management (2021)
Maintenance doses0.5mg, 1mg, 2mg weeklyTitration to 1.7mg or 2.4mg weekly
Weight loss evidence at label doseModerate (lower doses)14.9% average at 2.4mg (STEP 1)
Insurance treatmentBroad coverage with T2D diagnosisCovered by ~38% of large employer plans
MedicareCovered for T2DExcluded (weight loss exclusion)
Self-pay channelNovoCare $499/monthNovoCare $499/month
Cardiovascular outcomes dataYes (T2D population)Yes (SELECT: 20% MACE reduction with obesity + CVD)

About This Comparison

Our Editorial Standards

This weight loss provider comparison is independently researched by our editorial team. We compare telehealth services based on publicly available information including pricing, available treatments, service areas, and verified customer reviews.

Independent Research: We do not accept payment for rankings or favorable reviews
Affiliate Disclosure: We may earn commissions from qualifying purchases at no extra cost to you
Regular Updates: Content is reviewed and updated monthly for accuracy
Licensed Providers Only: All listed services employ US-licensed healthcare providers

Not Medical Advice: This comparison is for informational purposes only. We are not healthcare providers. Always consult with a licensed physician before starting any treatment. Read our full medical disclaimer and editorial policy.

Independent ResearchUnbiased provider comparisons
Fact-Checked InformationVerified against official sources
Regularly UpdatedContent reviewed monthly
Licensed Providers OnlyAll listed services are US-licensed

Ozempic vs Wegovy: Same Drug, Different Labels, Different Rules

Eric GoldWritten by Eric GoldEditor-in-Chief
9 min read

Ozempic and Wegovy generate more confusion than any product pair in telehealth, and the confusion has a simple resolution: they are the same molecule, semaglutide, made by the same company, Novo Nordisk, in different doses under different FDA labels. Ozempic carries the type 2 diabetes indication with maintenance doses up to 2mg weekly. Wegovy carries the chronic weight management indication with titration to 2.4mg weekly, the dose that produced 14.9% average body weight loss in the STEP 1 trial. The weight loss you have heard attributed to "Ozempic" is semaglutide pharmacology; the trademark difference exists because the FDA approves drugs per indication, and everything practical, which product your insurance covers, what prior authorization demands, which self-pay channel you use, and what you pay, flows from those labels. This comparison untangles the two products, the "Ozempic for weight loss" off-label question, and the real 2026 price paths for people with and without a diabetes diagnosis.

One Molecule, Two Products: Why Both Exist

Semaglutide is a GLP-1 receptor agonist: it mimics a gut hormone that slows stomach emptying, increases fullness signaling, and improves insulin response. Novo Nordisk first brought it to market as Ozempic in 2017 for type 2 diabetes, where its glucose control earned the approval. The weight loss seen in diabetes patients drove a second development program at a higher dose, and the 2.4mg dose became Wegovy, approved for chronic weight management in 2021 after the STEP trials.
Nothing about the molecule differs between pens. The differences are dose ceilings, 2mg for Ozempic versus 2.4mg for Wegovy, the label on file at the FDA, and the commercial infrastructure around each: separate savings programs, separate formulary listings, separate prior authorization criteria. Understanding that the products are commercially distinct but chemically identical is the key to every practical decision that follows, because the system routes you by diagnosis and label, not by chemistry.

The Label Decides What You Pay

Insurance formularies treat the two products as different drugs. With a type 2 diabetes diagnosis, Ozempic enjoys broad coverage: most commercial plans and Medicare Part D include it, typically landing copays at $25-$100 per month with the manufacturer savings card. Without a diabetes diagnosis, Ozempic coverage is not available to you, and plans verify the diagnosis during prior authorization.
Wegovy rides the weight management lane, where coverage reached 38% of large employer plans in 2025 per Kaiser Family Foundation data, up from 24% in 2023, but remains excluded by Medicare Part D and most state Medicaid programs. Where covered, prior authorization typically requires BMI of 30 or higher, or 27 with a weight-related condition, and the savings card can bring copays to $25. Where not covered, NovoCare Pharmacy sells both Wegovy and Ozempic directly to self-pay patients at $499 per month, and compounded semaglutide programs from telehealth providers run $99-$227 per month as the budget lane. The decision tree is short: diagnosis first, formulary second, channel third.

The "Ozempic for Weight Loss" Question

Prescribing Ozempic off-label for weight loss is legal, common during the shortage years, and mostly pointless today. Off-label prescribing is a normal physician prerogative, but insurance does not cover off-label Ozempic for weight, cash prices for the two products are identical at $499 through NovoCare, and Wegovy reaches a higher labeled dose with the weight-specific evidence base. The main historical reason for the workaround, Wegovy supply shortages, resolved in 2025.
Two situations keep the question alive. Prediabetes with obesity sits in a gray zone: it does not qualify for Ozempic diabetes coverage under most plans, so pursuing it is usually a dead end at prior authorization, and the honest route is Wegovy criteria or self-pay. And patients already on Ozempic for genuine type 2 diabetes get its weight benefits automatically; no product switch is needed, though a dose conversation with the prescriber sometimes is. If anyone offers you "cheap Ozempic" outside these channels without a prescription, you are looking at the gray market, where FDA warning letters, counterfeit pens, and unverifiable sourcing live.

Which Product Applies to You?

Your diagnosis answers the question, not your preference. With type 2 diabetes: Ozempic is your product, coverage is likely, and the weight effects come with it; ask your prescriber about dose optimization if weight is a co-goal. With obesity or overweight plus a weight-related condition, and no diabetes: Wegovy is your product, and the path is formulary check, prior authorization if covered, NovoCare at $499 if not, or compounded semaglutide from $99-$227 through providers like Strut Health, MEDVi, and TrimRx if the branded price does not fit.
One more comparison belongs in the decision: semaglutide versus tirzepatide. The SURMOUNT-5 head-to-head found tirzepatide (Zepbound) outperformed semaglutide 20.2% to 13.7% at 72 weeks, so if you are choosing a weight loss medication from scratch with budget flexibility, read our semaglutide vs tirzepatide comparison before settling the Ozempic-Wegovy question, which is really a question about which semaglutide package fits your insurance. Semaglutide holds the cardiovascular outcomes edge with the SELECT trial data showing 20% cardiac event reduction, which matters specifically for patients with existing heart disease.

Frequently Asked Questions

Are Ozempic and Wegovy the same drug?

Chemically, yes: both are semaglutide, made by Novo Nordisk, working identically as GLP-1 receptor agonists. Commercially and legally, no: Ozempic is FDA-approved for type 2 diabetes with maintenance doses up to 2mg weekly, while Wegovy is approved for chronic weight management with titration to 2.4mg weekly. The same molecule at overlapping doses behaves the same way in your body; a milligram of semaglutide does not know which pen it came from. What the label split changes is everything around the medication: which product your insurance will consider given your diagnosis, what the prior authorization criteria are, which savings program applies, and which clinical trial data formally supports your use. So the accurate answer to "is Ozempic the same as Wegovy" is: same medicine, different product wrappers, and the wrapper, not the medicine, determines your access and price. Your diagnosis picks the wrapper for you.

Can I get Ozempic prescribed for weight loss without diabetes?

A physician can legally prescribe it off-label, but the practical case for doing so has mostly evaporated. Insurance will not cover Ozempic for weight loss, plans verify the type 2 diabetes diagnosis during prior authorization, and label-shopping fails there rather than at the prescription stage. Cash-pay, Ozempic and Wegovy cost the same $499 per month through NovoCare Pharmacy, so the off-label route saves nothing while using the product with the lower labeled dose ceiling and without the weight-management evidence base at its label doses. The shortage era, when Wegovy was unavailable and Ozempic substitution made sense, ended in 2025. The remaining legitimate scenario: if you have diabetes and want the weight benefit, you already get it from Ozempic, and dose optimization is a prescriber conversation. If you do not have diabetes, pursue Wegovy through coverage or self-pay channels, or compounded semaglutide from $99-$227 monthly if branded pricing is out of reach.

Does Wegovy cause more weight loss than Ozempic?

At their respective label doses, yes, modestly, because Wegovy goes higher. The 2.4mg Wegovy maintenance dose produced the 14.9% average body weight loss in STEP 1; Ozempic tops out at 2mg for diabetes, where trials measured meaningful but smaller weight effects alongside glucose control. Semaglutide dose-response is real but flattens near the top: the difference between 2mg and 2.4mg is measurable in trials, not dramatic for an individual. In practice, diabetes patients on Ozempic 1-2mg routinely lose significant weight, and weight-management patients need the Wegovy titration schedule to reach the evidence-backed dose legitimately. If maximum weight loss is the actual goal and you are comparing molecules rather than labels, the more consequential comparison is semaglutide versus tirzepatide, where the head-to-head SURMOUNT-5 trial found tirzepatide ahead 20.2% to 13.7%, a far larger gap than any Ozempic-Wegovy dose difference. Within semaglutide, take whichever product your diagnosis and coverage support at the highest tolerated labeled dose.

Why does insurance cover Ozempic but not Wegovy?

Because formularies inherit a decades-old distinction: diabetes is universally treated as medical, while obesity treatment still fights legacy "lifestyle" exclusions written into many plans and into the Medicare Part D statute. Ozempic, carrying the diabetes label, slots into standard formulary tiers with routine coverage; Wegovy, carrying the weight label, hits explicit weight-loss exclusions that survive from an era of risky diet drugs. The exclusions are eroding, coverage grew from 24% of large employer plans in 2023 to 38% in 2025 as employers weigh the downstream cost of untreated obesity, but the asymmetry persists, and Medicare remains barred from covering weight-loss medications by statute. Two workarounds matter: Zepbound (tirzepatide) gained an obstructive sleep apnea indication in December 2024 that sidesteps weight exclusions for OSA patients, and comorbidity-based appeals sometimes succeed where initial authorizations fail. If your plan excludes Wegovy, ask HR during open enrollment; employer plan design, not clinical merit, is where this gets decided.

What do Ozempic and Wegovy cost without insurance in 2026?

The channels converged: NovoCare Pharmacy, the manufacturer direct-to-patient option, sells both products at $499 per month self-pay with free shipping and a valid prescription, roughly one-third of the $1,300-$1,400 retail list price either carries at a pharmacy counter. Below that branded tier sits compounded semaglutide from telehealth programs at $99-$227 per month, Strut Health at $99, MEDVi and TrimRx at $179, Sprout Health and SkinnyRx at $199, operating under individually prescribed formulation rules since the shortage ended. Above it, retail cash at list price makes sense for nobody. Annualized: about $6,000 for either brand through NovoCare, $1,200-$2,700 compounded. Two cost notes with clinical edges: HSA and FSA funds apply to all legitimate channels, and gray-market "cheap Ozempic" without a prescription is where counterfeits and FDA warnings concentrate; the price floor for real semaglutide with real medical oversight is the $99-$227 compounded tier, not a too-good-to-be-true online pen.

Sources & References

Our comparisons are informed by official sources and regulatory guidelines. We encourage readers to verify information with authoritative sources.

Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards

Ready to Compare Providers?

See which telehealth providers carry these treatments, at what price, and get started today.

Compare Weight Loss ProvidersEstimate Your Cost

Related Resources

Article

Best Weight Loss Providers

Weight Loss
Article

Treatment Cost Calculator

Medical Disclaimer: This comparison is for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication. Individual results and experiences may vary. Read our full medical disclaimer.